Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Ty21a in NMIBC
NCT03421236Phase 1Unknown
- Start
- Feb 2018
- Primary completion
- Dec 2021
- Modality
- Split/Subunit Vaccines, Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of typhoid vaccine, live oral in non-muscle-invasive bladder cancer (NMIBC). Primary endpoint: Adverse events at 6 weeks. Status: unknown.
02
Drugs
typhoid vaccine, live oral
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03421236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03421236.